<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18731" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Buspirone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wilson</surname>
            <given-names>Tyler K.</given-names>
          </name>
          <aff>Lincoln Memorial University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripp</surname>
            <given-names>Jayson</given-names>
          </name>
          <aff>CUSOM/Cape Fear Valley Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tyler Wilson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayson Tripp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18731.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Buspirone is an anxiolytic drug. Originally, the drug was developed as an antipsychotic but was found ineffective for psychosis, but it had useful anxiolytic features. Buspirone has recently come into favor, primarily due to its decreased side-effect profile compared to other anxiolytic treatments. Buspirone is primarily used to treat generalized anxiety disorder. It is a United States Food and Drug Administration-approved medicine for managing anxiety disorders or the short-term relief of anxiety symptoms. Off-labeled buspirone is used for the augmentation of unipolar depression. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of buspirone, pertinent for interprofessional team members for treating patients where buspirone is indicated.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of buspirone.</p></list-item><list-item><p>Outline the indications for initiating buspirone.</p></list-item><list-item><p>Summarize the contraindications associated with initiating buspirone.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance the use of buspirone and improve outcomes in disorders where indicated.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18731&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18731">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18731.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Buspirone is an anxiolytic first synthesized in 1968 and patented in 1975. Initially, the drug was being developed as an antipsychotic but was found ineffective for psychosis, but it had useful anxiolytic features. Buspirone has recently&#x000a0;come back into favor. This return to favor is primarily due to its decreased side-effect profile compared to other anxiolytic treatments.<xref ref-type="bibr" rid="article-18731.r1">[1]</xref></p>
        <p><bold>United States Food and Drug Administration-Approved Indication:&#x000a0;</bold>Management of anxiety disorders or the short-term relief of anxiety symptoms.&#x000a0;The efficacy of&#x000a0;buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis corresponds to generalized anxiety disorder (GAD).<xref ref-type="bibr" rid="article-18731.r2">[2]</xref>&#x000a0;Buspirone's use is primarily for treating GAD. Typically, it is used as&#x000a0;a second-line agent behind selective serotonin reuptake inhibitors (SSRIs) when a patient does not respond to or cannot tolerate the side effects of SSRIs. Buspirone has also been used as an augmentation agent to reduce SSRI's sexual side effects. Unlike benzodiazepines and barbiturates, there is no associated risk of physical dependence or withdrawal with buspirone use due to the lack of effects on gamma-aminobutyric acid (GABA) receptors. However, buspirone has little efficacy as an acute anxiolytic as the clinical effect typically takes 2 to 4 weeks to achieve. It is as effective as benzodiazepine treatment for GAD.<xref ref-type="bibr" rid="article-18731.r3">[3]</xref></p>
        <p><bold>Off-label Clinical Use:</bold>&#x000a0;Buspirone is used for the augmentation of unipolar depression. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed evidence suggesting that buspirone could be effective as augmentation, alongside SSRIs, for unipolar depression. Further studies have also found some&#x000a0;utility in subduing the sexual side effects of SSRIs and use as a single agent for the treatment of depression. Although the FDA does not approve these uses, evidence supports&#x000a0;that buspirone combined with melatonin can treat major depressive disorder and promote neurogenesis.<xref ref-type="bibr" rid="article-18731.r4">[4]</xref><xref ref-type="bibr" rid="article-18731.r5">[5]</xref></p>
        <p>It is essential to recognize that buspirone has no use in treating withdrawal symptoms from benzodiazepines, barbiturates, or alcohol. Again, this relates to the lack of GABA receptor activity. Furthermore, the effects of buspirone have been shown to diminish in patients who have had previous treatment with benzodiazepines.<xref ref-type="bibr" rid="article-18731.r6">[6]</xref>&#x000a0;A randomized controlled trial concluded that buspirone&#x000a0;improves central apnea, apnoea-hypopnoea index, and oxygen saturation in patients with heart failure.<xref ref-type="bibr" rid="article-18731.r7">[7]</xref>&#x000a0;Another study identified buspirone as a useful agent for treating gastroparesis and functional dyspepsia.<xref ref-type="bibr" rid="article-18731.r8">[8]</xref>&#x000a0;However, significant research in clinical trials is&#x000a0;necessary before approving the use of buspirone for the indications mentioned above in clinical practice.</p>
      </sec>
      <sec id="article-18731.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Buspirone is classified&#x000a0;in the azapirone drug class. It has a strong affinity for serotonin 5HT1a receptors, where it acts as a partial agonist, which some researchers believe produces the preponderance of clinical effects. It also has a weak affinity for serotonin 5HT2 receptors and acts as a weak antagonist of dopamine D2 autoreceptors. There is no effect on benzodiazepine GABA receptors. The underlying mechanism behind how the partial 5HT1a agonism translates into clinical results remains largely&#x000a0;unknown. It is proposed from increased serotonergic activity in the amygdala and other parts of the brain's anxiety/fear circuitry. Due to the delayed anxiolytic effects seen clinically, buspirone likely provides relief through adaptations in 5HT1a receptors.<xref ref-type="bibr" rid="article-18731.r3">[3]</xref></p>
        <p>Buspirone is primarily used to treat generalized anxiety disorder; however, it appears that buspirone may be useful in various other neurological and psychiatric disorders. Examples include attenuating side effects of Parkinson's disease therapy, ataxia, depression, social phobia, behavior disturbances following brain injury, and those accompanying Alzheimer disease, dementia, and attention deficit disorders. However, additional effectiveness studies are warranted before using buspirone for the disorders mentioned above.<xref ref-type="bibr" rid="article-18731.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Buspirone is rapidly absorbed and undergoes extensive first-pass metabolism. Peak plasma levels are attained within 40 to 90 minutes.<xref ref-type="bibr" rid="article-18731.r10">[10]</xref></p>
        <p><bold>Distribution:&#x000a0;</bold>Buspirone has approximately 86% plasma protein binding.&#x000a0;</p>
        <p><bold>Metabolism:&#x000a0;&#x000a0;</bold>Buspirone is metabolized primarily by oxidation by CYP3A4 and converts to hydroxylated derivatives and a pharmacologically active metabolite, 1-pyrimidinylpiperazine (1-PP).<xref ref-type="bibr" rid="article-18731.r11">[11]</xref></p>
        <p><bold>Excretion:&#x000a0;</bold>The elimination half-life of unchanged buspirone is approximately 2 to 3 hours. Buspirone is excreted in the urine as metabolites(29% to 63%); fecal excretion accounts for 18% to 38% of the dose.</p>
      </sec>
      <sec id="article-18731.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Buspirone is available in 5 mg, 7.5 mg, 10 mg, 15 mg, and 30 mg oral tablets. The initial recommended dose for GAD treatment is 15 mg daily, given as either 7.5 mg twice per day or 5 mg three times per day. Every 2 to 3 days, the dosage may be increased by 5 mg until the desired clinical response is achieved. The maximum daily dosage is 60 mg per day. In clinical trials, a typical range of therapeutic effects was between 20 to 30 mg per day in divided doses.</p>
        <p>Buspirone has seen occasional off-label use for pediatric anxiety disorders. The dosage has not been well established. In a pilot study of children aged 6 to 14, they were started on a daily dose of 5 mg and increased by 5 mg every week to a maximum daily dose of 20 mg. Another more extensive study with patients aged 6 to 17 had a higher maximum daily dose of 60 mg.<xref ref-type="bibr" rid="article-18731.r12">[12]</xref>&#x000a0;Food increases the bioavailability of buspirone; hence clinicians should counsel the patients to take buspirone with food or take it on an empty stomach. Consistency of dosage patterns is important.<xref ref-type="bibr" rid="article-18731.r10">[10]</xref>&#x000a0;Buspirone gets metabolized by cytochrome P450 (CYP3A4); hence evaluate&#x000a0;potential drug-drug interactions before an initial prescription.<xref ref-type="bibr" rid="article-18731.r13">[13]</xref></p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p><bold>Patients with hepatic impairment:&#x000a0;</bold>The measured bioavailability (using the steady-state area under the curve) increased 13-fold in patients with hepatic impairment; consider dose reduction in patients with hepatic impairment.</p>
        <p><bold>Patients with renal impairment: </bold>The bioavailability&#x000a0;of buspirone is increased&#x000a0;fourfold in patients with renal impairment (creatine clearance=10 to 70 mL/min/1.73 m); consequently,&#x000a0;consider dose reduction in patients with renal impairment.</p>
        <p><bold>Pregnancy considerations: </bold>Buspirone is a Category B risk in pregnancy.&#x000a0;On June 30, 2015, the FDA began implementation of the Pregnancy and Lactation Labeling Rule, which replaced the pregnancy letter category system (A, B, C, D, and X) with integrated narrative summaries of the risks of using a drug or biological product during pregnancy and lactation.&#x000a0;The effect of buspirone use during pregnancy on labor and delivery is unknown. However, reproductive studies in rats did not cause any adverse effects on animals.<xref ref-type="bibr" rid="article-18731.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Limited data indicate that maternal doses of buspirone up to 45 mg daily produce low levels of milk. No information is available on the long-term use of buspirone during breastfeeding; an alternate medication may be preferred, particularly while nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-18731.r15">[15]</xref></p>
      </sec>
      <sec id="article-18731.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Dizziness is a&#x000a0;common side effect that occurs in over 10% of patients.<xref ref-type="bibr" rid="article-18731.r16">[16]</xref></p>
        <p>According to FDA product labeling, the following reports of adverse events occurred in 1% to 10% of patients.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system: Abnormal dreams, ataxia, confusion, dizziness, drowsiness, excitement, headache, nervousness, numbness, outbursts of anger, paresthesia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ophthalmic: Blurred vision</p>
          </list-item>
          <list-item>
            <p>Otic: Tinnitus</p>
          </list-item>
          <list-item>
            <p>Cardiovascular: Chest pain</p>
          </list-item>
          <list-item>
            <p>Respiratory: Nasal congestion</p>
          </list-item>
          <list-item>
            <p>Dermatologic: Diaphoresis, skin rash</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal: Diarrhea, nausea, sore throat</p>
          </list-item>
          <list-item>
            <p>Neuromuscular and skeletal: Musculoskeletal pain, tremor, weakness</p>
          </list-item>
          <list-item>
            <p>Hepatic: isolated cases of serum enzyme elevations without jaundice&#x000a0;<xref ref-type="bibr" rid="article-18731.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>Clinicians can&#x000a0;mitigate these adverse drug reactions by continuing&#x000a0;therapy and gradual&#x000a0;titration to&#x000a0;an optimal therapeutic dose. Of note, buspirone has minimal sexual side effects. It has even been shown to help relieve the adverse sexual effects of SSRIs when given as an augmenting agent.<xref ref-type="bibr" rid="article-18731.r18">[18]</xref>&#x000a0;Patients should receive a warning about the possibility of central nervous system depression. In addition, clinicians&#x000a0;should inform&#x000a0;patients of the rare potential for akathisia (likely due to central dopamine antagonism) and serotonin syndrome.<xref ref-type="bibr" rid="article-18731.r19">[19]</xref>&#x000a0;Postmarketing surveillance reports cases of somnambulism (sleepwalking) associated with buspirone. However,&#x000a0;altered neurobiology due to&#x000a0;psychiatric disorders should also be considered.<xref ref-type="bibr" rid="article-18731.r20">[20]</xref>&#x000a0;QT prolongation has also been reported in patients with preexisting cardiac disorders.<xref ref-type="bibr" rid="article-18731.r21">[21]</xref></p>
      </sec>
      <sec id="article-18731.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications for Buspirone include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>History of hypersensitivity reaction with buspirone in the past</p>
          </list-item>
          <list-item>
            <p>Avoid the use of monoamine oxidase inhibitors (MAOI)&#x000a0;within 14 days before or after buspirone therapy. The aforementioned is due to the risk of developing serotonin syndrome and/or elevated blood pressure<xref ref-type="bibr" rid="article-18731.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Avoid buspirone in patients receiving reversible MAOIs such as linezolid or IV methylene blue due to the risk of serotonin syndrome.<xref ref-type="bibr" rid="article-18731.r23">[23]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18731.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Offer frequent follow-ups after initiating treatment to assess for therapeutic and adverse effects. Encourage patients to stay consistent with their medication schedule and whether they take it with food. As mentioned before, a therapeutic effect typically takes 2 to 4 weeks&#x000a0;for therapeutic effect. Often, many of the adverse effects will also lessen over time. However, healthcare providers&#x000a0;should closely monitor signs and symptoms of anaphylaxis, akathisia, and serotonin syndrome.<xref ref-type="bibr" rid="article-18731.r23">[23]</xref></p>
        <p>Buspirone is a&#x000a0;substrate of CYP3A4; clinicians should check for interactions that can alter its plasma concentration; this includes grapefruit juice, which can increase its concentration. Alcohol use can worsen any CNS sedation, and its use requires strict monitoring as well.<xref ref-type="bibr" rid="article-18731.r24">[24]</xref><xref ref-type="bibr" rid="article-18731.r25">[25]</xref>&#x000a0;Assess anxiety levels using the GAD-7 (general anxiety disorder-7) tool at baseline and follow-up visits to assess response to therapy. Similarly, clinicians can use the Hamilton Anxiety Scale (HAM-A)to objectify and rate a patient's anxiety severity.<xref ref-type="bibr" rid="article-18731.r26">[26]</xref><xref ref-type="bibr" rid="article-18731.r27">[27]</xref>&#x000a0;ISMP (Insitute for Safe Medical Practice) notes that buspirone may be easily confused with bupropion, and this&#x000a0;dispensing&#x000a0;error can be prevented&#x000a0;using tall man&#x000a0;lettering. Consequently,&#x000a0;healthcare providers&#x000a0;should monitor each visit for accurate dispensing.<xref ref-type="bibr" rid="article-18731.r28">[28]</xref></p>
      </sec>
      <sec id="article-18731.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Relative to other anxiolytics, buspirone has low toxicity and potential for abuse. There have been no deaths reported from a buspirone overdose alone. In pharmacological trials, healthy male patients were given up to 375 mg daily and developed nausea, vomiting, dizziness, drowsiness, miosis, and gastric distress. While buspirone overdose typically resolves with complete recovery, high suspicion of other medication overdoses should be maintained and investigated.<xref ref-type="bibr" rid="article-18731.r29">[29]</xref><xref ref-type="bibr" rid="article-18731.r30">[30]</xref>&#x000a0;In a literature review, multiple reports of movement disorders, including dyskinesia, akathisia, myoclonus, parkinsonism, and dystonia, have been reported.</p>
        <p>In case of movement disorder induced by buspirone, the drug should be discontinued, and in some instances, it may require therapy with trihexyphenidyl/benztropine(centrally acting anticholinergic medication) and additional supportive treatment.<xref ref-type="bibr" rid="article-18731.r19">[19]</xref>&#x000a0;Clinicians should use symptomatic and supportive measures and immediate gastric lavage in acute overdose. Healthcare providers must monitor respiration, pulse, and blood pressure, as in all drug overdose cases. Seizures can occur in rare instances which require treatment with benzodiazepines. It is important to note that no specific antidote is known for buspirone.<xref ref-type="bibr" rid="article-18731.r31">[31]</xref></p>
      </sec>
      <sec id="article-18731.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Before initiating buspirone therapy, it is essential to understand proper indications, dosing, adverse drug reactions, and toxicity.&#x000a0;The clinician should prescribe buspirone and counsel the patient on the risk vs. benefit ratio. The pharmacist must educate the patient on the safe use of the drug and ensure proper dosing. Additionally, the pharmacist must communicate with the physician if there is evidence of drug misuse in rare instances. In an era where drug abuse results in high mortality, healthcare workers are responsible for ensuring that patients only use buspirone for legitimate purposes. The literature review suggests that&#x000a0;buspirone has negligible abuse potential.<xref ref-type="bibr" rid="article-18731.r32">[32]</xref></p>
        <p>Nurses should monitor&#x000a0;for the signs and symptoms of anxiety during each follow-up visit.&#x000a0;Nursing staff can also provide patient counseling to reinforce the pharmacists' advice. Residents and medical students should counsel&#x000a0;the patient not to combine buspirone with other sedatives or alcohol. Patients who continue to get refills should be encouraged to seek counseling from a psychiatrist. Encourage individuals to be&#x000a0;patient at the initiation of therapy and follow up within a month to assess the effectiveness of buspirone therapy.</p>
        <p>The attending psychiatrist should evaluate the patient regularly and share their findings with the healthcare team. For example, emergency physicians and triage nurses should establish patent airway, breathing, and circulation in an overdose of buspirone. Moreover, the emergency department physician should notify the psychiatrist if the overdose is deliberate.</p>
        <p>Healthcare professionals should use&#x000a0;evidence-based medicine and be well-informed&#x000a0;about&#x000a0;the latest guidelines regarding the current status of buspirone in treating generalized anxiety disorder.<xref ref-type="bibr" rid="article-18731.r33">[33]</xref>&#x000a0;As depicted above, clinicians,&#x000a0;specialists, nurses, pharmacists, and other healthcare providers should closely collaborate with the patient on buspirone therapy. An interprofessional&#x000a0;team approach&#x000a0;can achieve optimal therapeutic results with minimal adverse effects leading to better patient outcomes. A systematic review and meta-analysis of seven randomized controlled trials concluded that interprofessional care and communication between clinicians, psychiatrists, specialty-trained nurses, and psychologists could significantly improve patient outcomes in anxiety disorders.<xref ref-type="bibr" rid="article-18731.r34">[34]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-18731.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18731&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18731">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18731/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18731">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18731.s11">
        <title>References</title>
        <ref id="article-18731.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiller</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The new and newer antianxiety agents.</article-title>
            <source>Med J Aust</source>
            <year>1989</year>
            <month>Dec</month>
            <day>4-18</day>
            <volume>151</volume>
            <issue>11-12</issue>
            <fpage>697</fpage>
            <page-range>697-701</page-range>
            <pub-id pub-id-type="pmid">2574409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garakani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murrough</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Freire</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Thom</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Buono</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Iosifescu</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>595584</fpage>
            <pub-id pub-id-type="pmid">33424664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howland</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Buspirone: Back to the Future.</article-title>
            <source>J Psychosoc Nurs Ment Health Serv</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>21</fpage>
            <page-range>21-4</page-range>
            <pub-id pub-id-type="pmid">26535760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Targum</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Nierenberg</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bleicher</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gage</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.</article-title>
            <source>J Psychiatr Res</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>1553</fpage>
            <page-range>1553-63</page-range>
            <pub-id pub-id-type="pmid">22998742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rafeyan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Papakostas</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2020</year>
            <month>May</month>
            <day>12</day>
            <volume>81</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32412697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chessick</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Thase</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Batista Miralha da Cunha</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kapczinski</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>de Lima</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>dos Santos Souza</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Azapirones for generalized anxiety disorder.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2006</year>
            <month>Jul</month>
            <day>19</day>
            <volume>2006</volume>
            <issue>3</issue>
            <fpage>CD006115</fpage>
            <pub-id pub-id-type="pmid">16856115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giannoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borrelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mirizzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Richerson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Emdin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Passino</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>312</fpage>
            <page-range>312-320</page-range>
            <pub-id pub-id-type="pmid">32441857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tack</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New developments in the treatment of gastroparesis and functional dyspepsia.</article-title>
            <source>Curr Opin Pharmacol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>43</volume>
            <fpage>111</fpage>
            <page-range>111-117</page-range>
            <pub-id pub-id-type="pmid">30245474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Politis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Buspirone: what is it all about?</article-title>
            <source>Brain Res</source>
            <year>2012</year>
            <month>Jun</month>
            <day>21</day>
            <volume>1461</volume>
            <fpage>111</fpage>
            <page-range>111-8</page-range>
            <pub-id pub-id-type="pmid">22608068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gammans</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Mayol</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>LaBudde</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Metabolism and disposition of buspirone.</article-title>
            <source>Am J Med</source>
            <year>1986</year>
            <month>Mar</month>
            <day>31</day>
            <volume>80</volume>
            <issue>3B</issue>
            <fpage>41</fpage>
            <page-range>41-51</page-range>
            <pub-id pub-id-type="pmid">3515929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmood</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sahajwalla</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-87</page-range>
            <pub-id pub-id-type="pmid">10320950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strawn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cornwall</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Mossman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Varney</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Keeshin</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Croarkin</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Buspirone in Children and Adolescents with Anxiety: A Review and Bayesian Analysis of Abandoned Randomized Controlled Trials.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-9</page-range>
            <pub-id pub-id-type="pmid">28846022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hohmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haefeli</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Mikus</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>CYP3A activity: towards dose adaptation to the individual.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2016</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>479</fpage>
            <page-range>479-97</page-range>
            <pub-id pub-id-type="pmid">26950050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Namazy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dinatale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinicians' Perspective of the New Pregnancy and Lactation Labeling Rule (PLLR): Results from an AAAAI/FDA Survey.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>1947</fpage>
            <page-range>1947-1952</page-range>
            <pub-id pub-id-type="pmid">32084595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Buspirone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Hanlon</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Review of buspirone's effects on human performance and related variables.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>1991</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>489</fpage>
            <page-range>489-501</page-range>
            <pub-id pub-id-type="pmid">1822316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Buspirone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31643299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Land&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Agren</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fahl&#x000e9;n</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-71</page-range>
            <pub-id pub-id-type="pmid">10350034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rissardo</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Caprara</surname>
                <given-names>ALF</given-names>
              </name>
            </person-group>
            <article-title>Buspirone-associated Movement Disorder: A Literature Review.</article-title>
            <source>Prague Med Rep</source>
            <year>2020</year>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-24</page-range>
            <pub-id pub-id-type="pmid">32191616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moses</surname>
                <given-names>TEH</given-names>
              </name>
              <name>
                <surname>Javanbakht</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>New-Onset Sleepwalking in a Patient Treated With Buspirone.</article-title>
            <source>J Clin Psychopharmacol</source>
            <string-date>2022 Jan-Feb 01</string-date>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-98</page-range>
            <pub-id pub-id-type="pmid">34928565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stock</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Zeber</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McNeal</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Banchs</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Psychotropic Pharmacotherapy Associated With QT Prolongation Among Veterans With Posttraumatic Stress Disorder.</article-title>
            <source>Ann Pharmacother</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>838</fpage>
            <page-range>838-848</page-range>
            <pub-id pub-id-type="pmid">29642718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunkley</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Sibbritt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.</article-title>
            <source>QJM</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>96</volume>
            <issue>9</issue>
            <fpage>635</fpage>
            <page-range>635-42</page-range>
            <pub-id pub-id-type="pmid">12925718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrison</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>610</fpage>
            <page-range>610-3</page-range>
            <pub-id pub-id-type="pmid">22452676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lilja</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kivist&#x000f6;</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Backman</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lamberg</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Grapefruit juice substantially increases plasma concentrations of buspirone.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>655</fpage>
            <page-range>655-60</page-range>
            <pub-id pub-id-type="pmid">9871430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rush</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers.</article-title>
            <source>Exp Clin Psychopharmacol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-38</page-range>
            <pub-id pub-id-type="pmid">9234037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;we</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;hler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schellberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herzog</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Herzberg</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population.</article-title>
            <source>Med Care</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-74</page-range>
            <pub-id pub-id-type="pmid">18388841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Hamilton Rating Scale for Anxiety (HAM-A).</article-title>
            <source>Occup Med (Lond)</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>601</fpage>
            <pub-id pub-id-type="pmid">26370845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaida</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The Institute for Safe Medication Practices and Poison Control Centers: Collaborating to Prevent Medication Errors and Unintentional Poisonings.</article-title>
            <source>J Med Toxicol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>262</fpage>
            <page-range>262-4</page-range>
            <pub-id pub-id-type="pmid">25840933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Razian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pourahmad</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Analysis of Toxicity Effects of Buspirone, Cetirizine and Olanzapine on Human Blood Lymphocytes: in Vitro Model.</article-title>
            <source>Curr Clin Pharmacol</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-127</page-range>
            <pub-id pub-id-type="pmid">29766823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Najam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Naeem</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Attenuation of methylphenidate-induced sensitization by co-administration of buspirone.</article-title>
            <source>Pak J Pharm Sci</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>585</fpage>
            <page-range>585-90</page-range>
            <pub-id pub-id-type="pmid">27087081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Catalano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Catalano</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Seizures associated with buspirone overdose: case report and literature review.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>1998</year>
            <season>Nov-Dec</season>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>347</fpage>
            <page-range>347-50</page-range>
            <pub-id pub-id-type="pmid">9844791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffith</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jasinski</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Casten</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Investigation of the abuse liability of buspirone in alcohol-dependent patients.</article-title>
            <source>Am J Med</source>
            <year>1986</year>
            <month>Mar</month>
            <day>31</day>
            <volume>80</volume>
            <issue>3B</issue>
            <fpage>30</fpage>
            <page-range>30-5</page-range>
            <pub-id pub-id-type="pmid">3963032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strawn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Geracioti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rajdev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clemenza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1057</fpage>
            <page-range>1057-1070</page-range>
            <pub-id pub-id-type="pmid">30056792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18731.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muntingh</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>van der Feltz-Cornelis</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>van Marwijk</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Spinhoven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Balkom</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Collaborative care for anxiety disorders in primary care: a systematic review and meta-analysis.</article-title>
            <source>BMC Fam Pract</source>
            <year>2016</year>
            <month>Jun</month>
            <day>02</day>
            <volume>17</volume>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">27250527</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
